Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $14.45, for a total value of $1,445,000.00. Following the transaction, the chief executive officer now directly owns 1,868,789 shares in the company, valued at approximately $27,004,001.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Christopher Richard Anzalone also recently made the following trade(s):
- On Tuesday, September 4th, Christopher Richard Anzalone sold 164,834 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $14.45, for a total value of $2,381,851.30.
NASDAQ:ARWR opened at $19.74 on Friday. Arrowhead Pharmaceuticals Inc has a 1-year low of $2.65 and a 1-year high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.62 million. equities analysts predict that Arrowhead Pharmaceuticals Inc will post -0.64 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in the business. RTW Investments LP increased its holdings in shares of Arrowhead Pharmaceuticals by 184.6% in the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after acquiring an additional 5,382,981 shares in the last quarter. OppenheimerFunds Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 23.9% in the first quarter. OppenheimerFunds Inc. now owns 7,807,644 shares of the biotechnology company’s stock worth $56,293,000 after acquiring an additional 1,507,644 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 108.1% in the second quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after acquiring an additional 3,679,986 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the first quarter worth about $12,706,000. Finally, Nexthera Capital LP bought a new stake in shares of Arrowhead Pharmaceuticals in the first quarter worth about $8,033,000. Institutional investors own 58.96% of the company’s stock.
Several equities analysts have weighed in on the company. Chardan Capital increased their target price on Arrowhead Pharmaceuticals from $17.50 to $24.50 and gave the company a “buy” rating in a research note on Thursday. B. Riley raised Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the company from $18.00 to $19.00 in a research note on Thursday. Cantor Fitzgerald set a $18.00 target price on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 16th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $20.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, August 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Arrowhead Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $18.36.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Further Reading: How to Invest in Marijuana Stocks
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.